|
Oncogenes and Tumor Suppressors
Citations 91-100 of 795 total displayed.
|
Past content
(since May 2000):
|
Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
- Alexandre Theocharides, Marjorie Boissinot, François Girodon, Richard Garand, Soon-Siong Teo, Eric Lippert, Pascaline Talmant, Andre Tichelli, Sylvie Hermouet, and Radek C. Skoda
Blood 2007; 110: 375-379.
[Abstract]
[Full text]
[PDF]
Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL
- Willem A. Dik, Bertrand Nadel, Grzegorz K. Przybylski, Vahid Asnafi, Piotr Grabarczyk, Jean Marc Navarro, Brenda Verhaaf, Christian A. Schmidt, Elizabeth A. Macintyre, Jacques J. M. van Dongen, and Anton W. Langerak
Blood 2007; 110: 388-392.
[Abstract]
[Full text]
[PDF]
Waldenström macroglobulinemia
- Arun Vijay and Morie A. Gertz
Blood 2007; 109: 5096-5103.
[Abstract]
[Full text]
[PDF]
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
- Hagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, Philippe Rousselot, Jerzy Holowiecki, Saengsuree Jootar, Tadeusz Robak, Nina Khoroshko, Tamas Masszi, Aleksander Skotnicki, Andrzej Hellmann, Andrey Zaritsky, Anatoly Golenkov, Jerald Radich, Timothy Hughes, Athena Countouriotis, and Neil Shah
Blood 2007; 109: 5143-5150.
[Abstract]
[Full text]
[PDF]
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells
- Hardik Modi, Tinisha McDonald, Su Chu, Jiing-Kuan Yee, Stephen J. Forman, and Ravi Bhatia
Blood 2007; 109: 5411-5421.
[Abstract]
[Full text]
[PDF]
Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis
- Magda Pinyol, Silvia Bea, Laura Plà, Vincent Ribrag, Jacques Bosq, Andreas Rosenwald, Elias Campo, and Pedro Jares
Blood 2007; 109: 5422-5429.
[Abstract]
[Full text]
[PDF]
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma
- Suzanne Trudel, Zhi Hua Li, Jennifer Rauw, Rodger E. Tiedemann, Xiao Yan Wen, and A. Keith Stewart
Blood 2007; 109: 5430-5438.
[Abstract]
[Full text]
[PDF]
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive chronic eosinophilic leukemia
- Jelena V. Jovanovic, Joannah Score, Katherine Waghorn, Daniela Cilloni, Enrico Gottardi, Georgia Metzgeroth, Philipp Erben, Helena Popp, Christoph Walz, Andreas Hochhaus, Catherine Roche-Lestienne, Claude Preudhomme, Ellen Solomon, Jane Apperley, Michela Rondoni, Emanuela Ottaviani, Giovanni Martinelli, Finella Brito-Babapulle, Giuseppe Saglio, Rüdiger Hehlmann, Nicholas C. P. Cross, Andreas Reiter, and David Grimwade, on behalf of the European LeukemiaNet
Blood 2007; 109: 4635-4640.
[Abstract]
[Full text]
[PDF]
Endogenous bcl-2 is not required for the development of Eµ-myc–induced B-cell lymphoma
- Priscilla N. Kelly, Hamsa Puthalakath, Jerry M. Adams, and Andreas Strasser
Blood 2007; 109: 4907-4913.
[Abstract]
[Full text]
[PDF]
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors
- Duonan Yu, Martin Carroll, and Andrei Thomas-Tikhonenko
Blood 2007; 109: 4936-4943.
[Abstract]
[Full text]
[PDF]
|
|
